The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer

Objective: To investigate the cost-effectiveness of adding Chinese-developed anti-PD-1 antibody tislelizumab to first-line pemetrexed-platinum chemotherapy in (1) a study population of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (nsqNSCLC) and without known se...

Full description

Bibliographic Details
Main Authors: Xia Luo, Zhen Zhou, Xiaohui Zeng, Qiao Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Pharmacology
Subjects:
cost-effectiveness
NSqNSCLC
tislelizumab
PD-L1 expression
smoking status
China
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.935581/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.935581/full

Similar Items